ORIGINAL: Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
2020-08-17 08:00 ET - News Release
VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Christopher J. Moreau, CEO of Algernon, will be providing an update on its two clinical trial programs on a BioPub webcast Wednesday August 19, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.
BioPub has been analyzing small-cap special situation biotech investments for 7 years to readers in over 40 countries.
BioPub.co Presents: Algernon Pharmaceuticals Corporate Update
When: August 19, 2020 12:00 PM EDT
Please click the link below to join the webinar:
https://us02web.zoom.us/j/87446125520
Or iPhone one-tap:
US: +16465588656, 87446125520# or +16699009128, 87446125520#
Or Telephone:
Dial (for higher quality, dial a number based on your current location):
US: +1 646 558 8656 or +1 669 900 9128 or +1 253 215 8782 or +1 301 715 8592 or +1 312 626 6799 or +1 346 248 7799
Webinar ID: 874 4612 5520
International numbers available: https://us02web.zoom.us/u/kdOyMvvDkk
About BioPub
BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don't get and presence at meetings others don't bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701